Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — 9M 2006 Earnings Presentation
20 slides from Novo Nordisk A/s Class B's earnings presentation, Oct 27, 2006
Slide 1: A focused healthcare company
Conference call 27 October 2006 A focused A focused healthcare healthcare company company First nine months of 2006 conference call 27 October 2006, 13.00 CET, 12.00 UK time, 7.00 New York time
Slide 2: Agenda
Conference call 27 October 2006 First nine months of 2006 Slide no 1 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results (Jesper Brandgaard, CFO) • Outlook for 2006 (Jesper Brandgaard, CFO)
Slide 3: Forward-looking statements
Conference call 27 October 2006 First nine months of 2006 Slide no 2 Forward-looking statements This presentation contains forward-looking statements as the term is defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements provide our expectations or forecasts of
Slide 4: Highlights from first nine months of 2006
Conference call 27 October 2006 First nine months of 2006 Slide no 3 Highlights from first nine months of 2006 Market development: • Sales growth driven by insulin analogues: +52% as reported • NovoSeven® growth continues: +13% as reported • Norditropin® shows strong performance: +21% as reported Re
Slide 5: Key products continue to drive growth
Conference call 27 October 2006 First nine months of 2006 Slide no 4 Key products continue to drive growth – first nine months of 2006 Sales as reported Growth analysis Other Norditropin® +2% Local currencies Growth Share of +21% growth 5% 9% Insulin analogues 52% 69% Diabetes care +17% Human insuli
Slide 6: Insulin analogues sales - solid analogue growth continues
Conference call 27 October 2006 First nine months of 2006 Slide no 5 Insulin analogues sales - solid analogue growth continues Analogue sales development Analogue sales as reported Levemir® +40% DKK 0.9bn 2,800 +214% NovoRapid® DKK 4.0bn 2,400 12% +39% NovoMix® DKK 2.8bn DKK million 2,000 +46% 1,600
Slide 7: A continued increase in analogue market share
Conference call 27 October 2006 First nine months of 2006 Slide no 6 A continued increase in analogue market share Novo Nordisk’s analogue Analogue penetration market share 39% 40% 35% Analogues 47% 30% 25% 7% 20% 15% Human insulin 10% 5% 0% Q1 Q2 Q1 Q2 2000 2006 2000 2006 Note: Quarterly data, volu
Slide 8: Insulin growth driven by NovoRapid and NovoMix
Conference call 27 October 2006 First nine months of 2006 Slide no 7 Insulin growth driven by NovoRapid® and NovoMix® NovoRapid® share of NovoMix® share of short-acting analogues premixed analogues 70% 70% 66% 60% 60% 52% 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% Q1 Q2 Q1 Q2 2002 2006 2002 2006
Slide 9: Levemir reinforces European analogue market leadership
Conference call 27 October 2006 First nine months of 2006 Slide no 8 Levemir® reinforces European analogue market leadership Share of total analogues Novo Nordisk’s share of long- in Europe acting analogues in Europe 22% 21% 60% Novo Nordisk Eli Lilly 20% Sanofi-Aventis 18% 50% 16% 40% 14% 12% 30% 1
Slide 10: NovoSeven - growth continues
Conference call 27 October 2006 First nine months of 2006 Slide no 9 NovoSeven® - growth continues NovoSeven® sales development Key observations • Growth in the third quarter of 1,600 +4% 4% as reported, 7% in local currencies 1,400 1,200 • Sales growth in all regions DKK million 1,000 • Sales growt
Slide 11: Norditropin - growth continues
Conference call 27 October 2006 First nine months of 2006 Slide no 10 Norditropin® - growth continues Norditropin® sales development Key observations +17% • Growth in the third quarter of 900 17% as reported, 21% in local 800 currencies 700 • Solid growth driven by market DKK million 600 share gains
Slide 12: Sales by region - first nine months of 2006
Conference call 27 October 2006 First nine months of 2006 Slide no 11 Sales by region - first nine months of 2006 Sales as reported Growth analysis Japan & Oceania 0% Europe Local Growth Share of +10% currencies growth 12% International Europe 10% 26% Operations North America 26% 47% +22% 19% 38% In
Slide 13: North America - continued solid growth driven by insulin analogues
Conference call 27 October 2006 First nine months of 2006 Slide no 12 North America - continued solid growth driven by insulin analogues North America sales development Key observations Index local currencies • Strong growth in the third 350 quarter of 24% as reported, % 29% in local currencies 300
Slide 14: Development portfolio – diabetes care
Conference call 27 October 2006 First nine months of 2006 Slide no 13 Development portfolio – diabetes care Compound Type Indication Phase Levemir® Insulin analogue Types 1+2 Launched in the US, Europe, etc. Filed in JP NovoMix® 50 and 70 Insulin analogue Types 1+2 Approved in Europe Filed in the US
Slide 15: Development portfolio – haemostasis
Conference call 27 October 2006 First nine months of 2006 Slide no 14 Development portfolio – haemostasis Compound Indication Phase NovoSeven® Acquired Haemophilia Approved EU, US and JP NovoSeven® Trauma Phase 3 NovoSeven® Intracerebral haemorrhage Phase 3 NovoSeven® Prophylaxis Phase 2 completed N
Slide 16: Development portfolio - other biopharmaceuticals
Conference call 27 October 2006 First nine months of 2006 Slide no 15 Development portfolio - other biopharmaceuticals Compound Indication Phase Activelle® low dose Hormone replacement therapy Filed in Europe and the US Vagifem® low dose Hormone replacement therapy Phase 3 Norditropin® APCD1 Phase 2
Slide 17: Financial results
Conference call 27 October 2006 First nine months of 2006 Slide no 16 Financial results DKK million 9M 2006 9M 2005 % change Sales 28,256 24,334 16 Gross profit 21,252 17,681 20 Sales and distribution costs 8,277 6,808 22 Research and development costs 4,406 3,534 25 Administrative expenses 1,742 1,
Slide 18: Currency development USD
Conference call 27 October 2006 First nine months of 2006 Slide no 17 Currency development USD 660 640 628 620 612 621 USD/DKK 600 593 594* 585 592 580 Spot rate 568 560 Quarterly average Annual average 540 Q105 Q205 Q305 Q405 Q106 Q206 Q306 Q406 *The spot rate as of 23 October
Slide 19: Outlook 2006
Conference call 27 October 2006 First nine months of 2006 Slide no 18 Outlook 2006 • Sales growth expectations: Key currency rates • maintained at 13−15% as reported DKK 2005 2006 Current • Operating profit growth expectations: per 100 average ytd avg rate* USD 600 600 594 • maintained at around 13%
Slide 20: Investor information
Conference call 27 October 2006 First nine months of 2006 Slide no 19 Investor information Share information Investor Relations contacts Novo Nordisk A/S Novo Nordisk’s B shares are Investor Relations listed on the stock exchanges in Novo Allé, DK-2880 Bagsværd Fax (+45) 4443 6633 Copenhagen and Lon